The role of HER2 in cancer therapy and targeted drug delivery

W Tai, R Mahato, K Cheng - Journal of controlled release, 2010 - Elsevier
HER2 is highly expressed in a significant proportion of breast cancer, ovarian cancer, and
gastric cancer. Since the discovery of its role in tumorigenesis, HER2 has received great …

Peptides used in the delivery of small noncoding RNA

RS Shukla, B Qin, K Cheng - Molecular pharmaceutics, 2014 - ACS Publications
RNA interference (RNAi) is an endogenous process in which small noncoding RNAs,
including small interfering RNAs (siRNAs) and microRNAs (miRNAs), post-transcriptionally …

Multi-modal multi-instance learning using weakly correlated histopathological images and tabular clinical information

H Li, F Yang, X **ng, Y Zhao, J Zhang, Y Liu… - … Image Computing and …, 2021 - Springer
The fusion of heterogeneous medical data is essential in precision medicine to assist
medical experts in treatment decision-making. However, there is often little explicit …

Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance

M Lei, G Ma, S Sha, X Wang, H Feng, Y Zhu, X Du - Drug delivery, 2019 - Taylor & Francis
Multidrug resistance (MDR) remains one of the major reasons for inefficiency of many
chemotherapeutic agents in cancer therapy. In this study, a D-α-tocopheryl polyethylene …

[HTML][HTML] Development of a biocompatible copolymer nanocomplex to deliver VEGF siRNA for triple negative breast cancer

Z Zhao, Y Li, R Shukla, H Liu, A Jain, A Barve… - Theranostics, 2019 - ncbi.nlm.nih.gov
Triple negative breast cancer (TNBC) is the most difficult breast cancer subtype to treat.
TNBC patients have significantly higher expression of vascular endothelial growth factor …

Effective gene silencing by multilayered siRNA‐coated gold nanoparticles

SK Lee, MS Han, S Asokan, CH Tung - Small, 2011 - Wiley Online Library
Small interfering RNA (siRNA) has been widely proposed to treat various diseases by
silencing genes, but its delivery remains a challenge. A well controlled assembly approach …

Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo

SJ Lee, S Yook, JY Yhee, HY Yoon, MG Kim… - Journal of Controlled …, 2015 - Elsevier
Cancer is a multifactorial disease which involves complex genetic mutation and
dysregulation. Combinatorial RNAi technology and concurrent multiple gene silencing are …

Expression profile and functional activity of peptide transporters in prostate cancer cells

W Tai, Z Chen, K Cheng - Molecular pharmaceutics, 2013 - ACS Publications
Peptide transporters are expressed predominantly in intestinal and renal epithelial cells. The
functional expression of peptide transporters is also identified in other types of tissues, such …

Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy

HG Shin, HR Yang, A Yoon, S Lee - International Journal of Molecular …, 2022 - mdpi.com
Cancer is the second leading cause of death worldwide after cardiovascular diseases.
Harnessing the power of immune cells is a promising strategy to improve the antitumor effect …

Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex

RS Shukla, A Jain, Z Zhao, K Cheng - … : Nanotechnology, Biology and …, 2016 - Elsevier
Despite the importance of siRNA delivery systems, understanding of their intracellular fate
remains elusive. We recently developed a multi-component siRNA nanocomplex to deliver …